2 1 Shi Ji Jing Ji Bao Dao·2025-12-12 14:17Group 1: 恒瑞医药 - Company announced that its subsidiary received approval for clinical trials of HRS9531 injection, a novel dual agonist targeting GIPR and GLP-1R, aimed at treating metabolic dysfunction-related fatty liver disease (MASH) [1] - HRS9531 injection is expected to improve blood sugar levels and reduce weight by regulating glucose and lipid metabolism, suppressing appetite, and enhancing insulin sensitivity [1] - There are currently no similar drugs approved globally for the MASH indication, and the total R&D investment for HRS9531 has reached approximately 519 million yuan [1] Group 2: 青岛港 - Company announced the termination of its cash acquisition of 100% equity in Rizhao Port Oil Products Terminal Co., Ltd. and 50% equity in Rizhao Shihua Oil Terminal Co., Ltd. due to significant impacts from Rizhao Shihua being listed on the U.S. Specially Designated Nationals list [2] - The termination agreement was signed on December 12, 2025, and will not incur any breach of contract or other liabilities, nor will it adversely affect the company's operations or financial status [2] Group 3: 隆盛科技 - Company plans to invest approximately 350 million yuan to establish a humanoid intelligent robot innovation center in Wuxi, with a focus on R&D and industrialization of humanoid robots [3] - The project will involve a total investment of about 350 million yuan, with the company covering around 200 million yuan for land and construction, while its subsidiary will invest approximately 150 million yuan for the center's operation [3] Group 4: *ST沪科 - Company received a notice from the China Securities Regulatory Commission regarding an investigation into suspected violations of information disclosure laws [4] - The company stated that its production and operations are normal and that the investigation will not have a significant impact on its management [4] Group 5: 永鼎股份 - Company clarified that it does not directly manufacture controllable nuclear fusion devices, despite being listed as a related concept stock [5] - The revenue from its subsidiary related to this area accounts for less than 1% of the company's total revenue and is currently operating at a loss [5] - The controlling shareholder reduced its stake by 1.336 million shares during a period of abnormal stock trading [5] Group 6: 亚翔集成 - Company announced that its shareholder EVER CREATIVE reduced its stake by 414,000 shares on December 11, 2025, amid significant stock price fluctuations [6] - The stock experienced a cumulative price deviation exceeding 20% over two consecutive trading days [6] Group 7: 恩捷股份 - Company plans to acquire 100% of Qingdao Zhongke Hualian New Materials Co., Ltd. through a share issuance and will resume trading on December 15 [8] Group 8: 芯原股份 - Company announced the termination of its plan to acquire 97% of Chipwise Technology due to discrepancies between the management's core demands and market conditions [9] - The decision was made to protect the interests of the company and its shareholders [9]